Key result
Rotavirus vaccines maintain global effectiveness against severe disease and mortality with a favorable benefit-risk profile.
Why the study?
Do rotavirus vaccines reduce severe disease and mortality in infants globally?
Do rotavirus vaccines reduce severe disease and mortality in infants globally?
Rotavirus vaccines have proven effective globally in reducing severe pediatric diarrhea and mortality, though geographic disparities in effectiveness remain an area of ongoing research.
Rotasiil sustains protection against severe rotavirus gastroenteritis to age 2 in high-mortality settings; leaves open durability beyond 2 years and all-cause diarrhea effects.
Rotavirus is a major cause of severe pediatric diarrhea worldwide. In 2006, 2 live, oral rotavirus vaccines, Rotarix and RotaTeq, were licensed for use in infants and were rapidly adopted in many high- and middle-income settings where efficacy had been demonstrated in clinical trials. Following completion of successful trials in low-income settings, the World Health Organization (WHO) recommended rotavirus vaccination for all infants globally in 2009. In 2018, 2 new rotavirus vaccines, Rotasiil and Rotavac, were prequalified by WHO, expanding global availability. As of March 2021, rotavirus vaccines have been introduced nationally in 106 countries. Since, Rotavirus vaccines have demonstrated effectiveness against severe disease and mortality, even among age groups in eligible for vaccination. Cross-genotypic protection has been demonstrated, and the favorable benefit-risk profile of these vaccines continues to be confirmed. Ongoing research seeks to better understand reasons for the geographic disparities in effectiveness observed, in order to optimize vaccine strategies worldwide.
No takes yet. Share an insight, caveat, or question.
Burke et al. (2021) conducted a review in Rotavirus infection. Rotavirus vaccines was evaluated. Rotavirus vaccines have demonstrated effectiveness against severe disease and mortality globally, maintaining a favorable benefit-risk profile following national introduction in 106 countries.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: